Alabama settles with a clinic over unapproved weight-loss drugs

Alabama Attorney General Steve Marshall announced on January 12, 2026, that the state has settled a lawsuit against Aurora IV and Wellness, a Cullman-based IV infusion clinic, and its owners, Amanda and Chris Medders.^[1] The settlement requires the Medderses to pay $17,267.50 in damages to consumers who filed complaints with the Attorney General's office, plus $7,000 in penalties and fees to the state.^[1] The clinic is permanently closed, and the owners are barred from working in the healthcare industry in any role involving direct patient treatment. Amanda Medders also surrendered her nursing license to the Alabama Board of Nursing.^[1]

The case began in November 2025, when the Attorney General obtained a temporary restraining order against the business after filing suit under Alabama's Deceptive Trade Practices Act.^[1] State investigators said the clinic advertised its weight-loss injections as "pharmaceutical-grade," but the drugs it actually gave patients were research-grade versions of semaglutide and tirzepatide, the active ingredients in GLP-1 medicines like Ozempic, Wegovy, Mounjaro and Zepbound.^[1] According to the Attorney General's office, the manufacturer of those research-grade products had stated explicitly that they were intended only for laboratory research, not for use in people.^[1]

"Exploiting the need for medical GLP-1 weight-loss medication by using unapproved, research-grade chemicals on unsuspecting patients is an extremely reckless form of consumer deception," Marshall said in the announcement, adding that "this type of dangerous disregard for patient safety will not be tolerated in Alabama."^[1] The Attorney General credited the Alabama Board of Nursing, the Alabama Board of Medical Examiners, and the Cullman Police Department with helping investigate the clinic.^[1]

Why it matters for patients

This settlement is a state-level enforcement action, separate from the FDA's own oversight of drug safety. It shows that in addition to federal regulators, state attorneys general and licensing boards can investigate and shut down clinics that sell unapproved GLP-1 products, and can strip providers of their professional licenses.^[1]

The core problem described in the settlement is one that has come up elsewhere in the compounding and wellness-clinic space: products labeled or marketed as medical-grade semaglutide or tirzepatide that are actually research chemicals never evaluated by regulators for use in humans. The Attorney General's office said the manufacturer itself had labeled the drugs for laboratory research only, not patient treatment.^[1] Patients who received injections at clinics operating this way had no way of knowing, from the marketing alone, that they were being given a product not intended for human use.^[1]

For consumers considering GLP-1 treatment from clinics outside a traditional pharmacy or prescriber network, this case is a reminder that state enforcement actions exist and that some providers have been found, through investigation, to have misrepresented what they were administering.^[1] The sources here do not say whether any patients who received the injections reported specific health harms, only that the state's investigation and lawsuit were based on the products being unapproved for human use and the marketing being deceptive.^[1]

What happens next

The sources do not indicate any further legal proceedings tied to this specific case beyond the settlement terms announced January 12, 2026.^[1] It is not yet known from the available information whether other clinics in Alabama or elsewhere are under similar investigation, or whether the Medderses face additional licensing or criminal consequences beyond what is described in the settlement.^[1]